- Home
- STTK vs PBYI Comparison
STTK vs PBYI Comparison
Compare STTK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PBYI
- Stock Information
- Founded
- STTK 2016
- PBYI 2010
- Country
- STTK United States
- PBYI United States
- Employees
- STTK N/A
- PBYI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- PBYI Health Care
- Exchange
- STTK Nasdaq
- PBYI Nasdaq
- Market Cap
- STTK 173.6M
- PBYI 176.1M
- IPO Year
- STTK 2020
- PBYI N/A
- Fundamental
- Price
- STTK $3.86
- PBYI $2.39
- Analyst Decision
- STTK Strong Buy
- PBYI Strong Buy
- Analyst Count
- STTK 3
- PBYI 1
- Target Price
- STTK $10.67
- PBYI $7.00
- AVG Volume (30 Days)
- STTK 150.7K
- PBYI 392.8K
- Earning Date
- STTK 11-07-2024
- PBYI 10-31-2024
- Dividend Yield
- STTK N/A
- PBYI N/A
- EPS Growth
- STTK N/A
- PBYI N/A
- EPS
- STTK N/A
- PBYI 0.18
- Revenue
- STTK $4,123,999.00
- PBYI $219,143,000.00
- Revenue This Year
- STTK $164.45
- PBYI N/A
- Revenue Next Year
- STTK N/A
- PBYI N/A
- P/E Ratio
- STTK N/A
- PBYI $12.77
- Revenue Growth
- STTK 380.09
- PBYI N/A
- 52 Week Low
- STTK $1.33
- PBYI $2.13
- 52 Week High
- STTK $11.76
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- STTK 57.18
- PBYI 37.64
- Support Level
- STTK $3.37
- PBYI $2.23
- Resistance Level
- STTK $3.75
- PBYI $2.42
- Average True Range (ATR)
- STTK 0.24
- PBYI 0.17
- MACD
- STTK 0.08
- PBYI 0.00
- Stochastic Oscillator
- STTK 88.57
- PBYI 27.59
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.